These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19169090)

  • 1. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
    Rigas M; Tandan R; Sterling RJ
    J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.
    Souayah N; Hasan A; Khan HM; Yacoub HA; Jafri M
    J Clin Neuromuscul Dis; 2011 Jun; 12 Suppl 4():S1-10. PubMed ID: 22361589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment].
    Léger JM; Viala K; Maisonobe T; Bouche P
    Bull Acad Natl Med; 2007 Oct; 191(7):1395-407; discussion 1407-9. PubMed ID: 18447061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
    Debes A; Bauer M; Kremer S
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
    Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
    Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
    Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
    Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study.
    Stangel M; Kiefer R; Pette M; Smolka MN; Marx P; Gold R
    J Neurol; 2003 Jul; 250(7):818-21. PubMed ID: 12883923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
    Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
    Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria.
    Mitzel-Kaoukhov H; Staubach P; Müller-Brenne T
    Ann Allergy Asthma Immunol; 2010 Mar; 104(3):253-8. PubMed ID: 20377115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
    Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
    Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Not all intravenous immunoglobulin preparations are equally well tolerated.
    Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
    Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
    Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
    Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
    Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
    Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
    Stein MR; Koterba A; Rodden L; Berger M
    Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins--interim results on drug safety of an ongoing study. IVIG study group.
    Poehlau D
    Mult Scler; 2000 Oct; 6 Suppl 2():S21-3. PubMed ID: 11188774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin administration: an evaluation of vital sign monitoring.
    Camp-Sorrell D; Wujcik D
    Oncol Nurs Forum; 1994 Apr; 21(3):531-5. PubMed ID: 8052549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.